The European Medicines Agency (EMA) remains “firmly convinced” that the benefits of the AstraZeneca vaccine against Covid-19 outweigh the risks of side effects and has so far found no “evidence” to show that cases of thrombosis recorded in people who have received this vaccine are related to its administration.
This has been assured by the managing director of the EMA, Emer Cooke, in a press conference in which she explained that the organization is evaluating "in depth" the cases of clots that have been detected by the Member States to determine if they are effectively related to the AstraZeneca vaccine or if they are a “coincidence”.
